Cancer Causes & Control

, Volume 19, Issue 8, pp 887–894 | Cite as

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

  • Arti Parikh-Patel
  • Richard H. White
  • Mark Allen
  • Rosemary Cress
Original Paper

Abstract

Objective

We conducted a retrospective cohort study to examine cancer risk in a large cohort of systemic lupus erythematosus (SLE) patients in California.

Methods

The cohort consisted of individuals with SLE derived from statewide patient discharge data during the period 1991–2002. SLE patients were followed using cancer registry data to examine patterns of cancer development. Standardized incidence ratios (SIRs) and 95% CI were calculated to compare the observed to expected numbers of cancers based on age-, race-, and sex-specific incidence rates in the California population.

Results

The 30,478 SLE patients were observed for 157,969 person-years. A total of 1,273 cancers occurred within the observation interval. Overall cancer risk was significantly elevated (SIR = 1.14, 95% CI = 1.07–1.20). SLE patients had higher risks of vagina/vulva (SIR = 3.27, 95% CI = 2.41–4.31) and liver cancers (SIR = 2.70, 95% CI = 1.54–4.24). Elevated risks of lung, kidney, and thyroid cancers and several hematopoietic malignancies were also observed. Individuals had significantly lower risks of several screenable cancers, including breast, cervix, and prostate.

Conclusions

These data suggest that risks of several cancer types are elevated among SLE patients. Detailed studies of endogenous and exogenous factors that drive these associations are needed.

Keywords

Cancer Systemic lupus erythematosus Malignancy Autoimmune diseases Hematologic neoplasms 

References

  1. 1.
    Abu-Shakra M, Buskila D, Shoenfeld Y (2000) SLE and cancer. In: Shoenfeld Y, Gershwin ME (eds) Cancer and autoimmunity. Elsevier Science, pp 31–40Google Scholar
  2. 2.
    Abu-Shakra M, Gladman DD, Urowitz MB (2004) Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 3:418–420PubMedCrossRefGoogle Scholar
  3. 3.
    Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27:685–691PubMedGoogle Scholar
  4. 4.
    Urowitz MB, Gladman DD (2000) How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 39:238–244CrossRefGoogle Scholar
  5. 5.
    Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24:1061–1065PubMedGoogle Scholar
  6. 6.
    Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490PubMedCrossRefGoogle Scholar
  7. 7.
    Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509PubMedCrossRefGoogle Scholar
  8. 8.
    Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71PubMedCrossRefGoogle Scholar
  9. 9.
    Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768PubMedCrossRefGoogle Scholar
  10. 10.
    Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439PubMedCrossRefGoogle Scholar
  11. 11.
    Ragnarsson O, Grondal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691PubMedCrossRefGoogle Scholar
  12. 12.
    Xu Y, Wiernik PH (2001) Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 10:841–850PubMedCrossRefGoogle Scholar
  13. 13.
    Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRefGoogle Scholar
  14. 14.
    Ramsey-Goldman R, Mattai SA, Schilling E et al (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222PubMedGoogle Scholar
  15. 15.
    Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22:1478–1482PubMedGoogle Scholar
  16. 16.
    Kinlen LJ (1992) Malignancy in autoimmune diseases. J Autoimmun 5 (Suppl A):363–371PubMedCrossRefGoogle Scholar
  17. 17.
    Bernatsky S, Clarke A, Ramsey-Goldman R (2002) Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4:351–358PubMedCrossRefGoogle Scholar
  18. 18.
    Oertel SH, Riess H (2002) Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res 159:1–8PubMedGoogle Scholar
  19. 19.
    Bhalla R, Ajmani HS, Kim WW, Swedler WI, Lazarevic MB, Skosey JL (1993) Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20:1316–1320PubMedGoogle Scholar
  20. 20.
    Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL (1982) Cancer in connective tissue disease. Arthritis Rheum 25:1130–1133PubMedCrossRefGoogle Scholar
  21. 21.
    Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390PubMedCrossRefGoogle Scholar
  22. 22.
    Green JA, Dawson AA, Walker W (1978) Systemic lupus erythematosus and lymphoma. Lancet 2:753–756PubMedCrossRefGoogle Scholar
  23. 23.
    Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054PubMedCrossRefGoogle Scholar
  24. 24.
    Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400PubMedCrossRefGoogle Scholar
  25. 25.
    Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500–504PubMedCrossRefGoogle Scholar
  26. 26.
    Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39:1147–1152CrossRefGoogle Scholar
  27. 27.
    Services USDoHaH (2000) ICD-9-CM: international classification of diseases, 9th Revision, Clinical modification, 6th edition, Washington DCGoogle Scholar
  28. 28.
    Cancer Reporting in California (1997) Standards for automated reporting. California cancer reporting system standards, vol II. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997Google Scholar
  29. 29.
    Cancer Reporting in California (1997) Data standards for regional registries and California Cancer Registry. California cancer reporting system standards, vol III. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, December 1997Google Scholar
  30. 30.
    Cancer Reporting in California (1998) Reporting procedures for physicians. California cancer reporting system standards, vol IV. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, January 1998Google Scholar
  31. 31.
    Cancer Reporting in California (1997) Abstracting and coding procedures for hospitals. California cancer reporting system standards, vol I. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, June 1997Google Scholar
  32. 32.
    Chen VW, Howe HL, Wu XC (2000) Cancer in North America, 1993–1997. Volume I: incidence. North American Association of Central Cancer Registries, SpringfieldGoogle Scholar
  33. 33.
    Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMedGoogle Scholar
  34. 34.
    Integrity Program (1999) Data reengineering environment software. Vality Technology Inc., BostonGoogle Scholar
  35. 35.
    Allen M (2001) Validation of OSHPD and CCR insurance status. California Association of Central Cancer Registries Technical Conference, Riverside, CAGoogle Scholar
  36. 36.
    Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, GenevaGoogle Scholar
  37. 37.
    Breslow NE, Day NE (1987) Statistical methods in cancer research, Volume II: the design and analysis of cohort studies. International Agency for Research on Cancer, LyonGoogle Scholar
  38. 38.
    Bernatsky S, Boivin JF, Joseph L et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. J Rheumatol 29:2551–2554PubMedGoogle Scholar
  39. 39.
    Bruce IN, Gladman DD, Urowitz MB (1998) Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 16:435–440PubMedGoogle Scholar
  40. 40.
    McAlindon T, Giannotta L, Taub N, D’Cruz D, Hughes G (1993) Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:720–724PubMedCrossRefGoogle Scholar
  41. 41.
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRefGoogle Scholar
  42. 42.
    Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363–2368PubMedGoogle Scholar
  43. 43.
    Ahmed MM, Berney SM, Wolf RE et al (2006) Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331:252–256PubMedCrossRefGoogle Scholar
  44. 44.
    Berthier S, Mougin C, Vercherin P et al (1999) Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 20:128–132PubMedGoogle Scholar
  45. 45.
    Tam LS, Chan AY, Chan PK, Chang AR, Li EK (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50:3619–3625PubMedCrossRefGoogle Scholar
  46. 46.
    Thomas RH, Ridley CM, Black MM (1985) Lichen sclerosus et atrophicus associated with systemic lupus erythematosus. J Am Acad Dermatol 13:832–833PubMedCrossRefGoogle Scholar
  47. 47.
    Gibbons RB, Westerman E (1988) Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31:1552–1554PubMedCrossRefGoogle Scholar
  48. 48.
    Lishner M, Hawker G, Amato D (1990) Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematol 84:38–39PubMedGoogle Scholar
  49. 49.
    Rosenthal NS, Farhi DC (1996) Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol 106:676–679PubMedGoogle Scholar
  50. 50.
    Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE (1992) Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 19:1625–1627PubMedGoogle Scholar
  51. 51.
    Elliott RW, Essenhigh DM, Morley AR (1982) Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J (Clin Res Ed) 284:1160–1161Google Scholar
  52. 52.
    Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379PubMedGoogle Scholar
  53. 53.
    Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121PubMedGoogle Scholar
  54. 54.
    Bernatsky S, Boivin JF, Joseph L et al (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784PubMedCrossRefGoogle Scholar
  55. 55.
    Alarcon GS, Calvo-Alen J, McGwin G et al (2006) Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 65(9):1168–1174PubMedCrossRefGoogle Scholar
  56. 56.
    Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA (2006) Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 33:45–49PubMedGoogle Scholar
  57. 57.
    Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 40:1594–1600PubMedCrossRefGoogle Scholar
  58. 58.
    Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE (2007) A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 66(12):1627–1632PubMedCrossRefGoogle Scholar
  59. 59.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Arti Parikh-Patel
    • 1
  • Richard H. White
    • 2
  • Mark Allen
    • 1
  • Rosemary Cress
    • 1
    • 3
  1. 1.California Cancer RegistryPublic Health InstituteSacramentoUSA
  2. 2.Department of Internal MedicineUniversity of California Davis School of MedicineSacramentoUSA
  3. 3.Department of Public Health SciencesUniversity of CaliforniaDavisUSA

Personalised recommendations